The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Open accessAbstract
BACKGROUND: CC chemokine receptor 5 antagonists are a new class of antiretroviral agents. METHODS: We conducted two double-blind, placebo-controlled, phase 3 studies--Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2--with patients who had R5 human immunodeficiency virus type 1 (HIV-1) only. They had been treated with or had resistance to three antiretroviral-drug classes and had HIV-1 RNA levels of more than 5000 copies per milliliter. The patients were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy (OBT) based on treatment history and drug-resistance testing. Safety and efficacy were assessed after 48 weeks. RESULTS: A total of 1049 patients received the randomly assigned study drug; the mean baseline HIV-1 RNA level was 72,400 copies per milliliter, and the median CD4 cell count was 169 per cubic millimeter. At 48 weeks, in both studies, the mean change in HIV-1 RNA from baseline was greater with maraviroc than with placebo: -1.66 and -1.82 log(10) copies per milliliter with the once-daily and twice-daily regimens, respectively, versus -0.80 with placebo in MOTIVATE 1, and -1.72 and -1.87 log(10) copies per milliliter, respectively, versus -0.76 with placebo in MOTIVATE 2. More patients receiving maraviroc once or twice daily had HIV-1 RNA levels of less than 50 copies per milliliter (42% and 47%, respectively, vs. 16% in the placebo group in MOTIVATE 1; 45% in both maraviroc groups vs. 18% in MOTIVATE 2; P<0.001 for both comparisons in each study). The change from baseline in CD4 counts was also greater with maraviroc once or twice daily than with placebo (increases of 113 and 122 per cubic millimeter, respectively, vs. 54 in MOTIVATE 1; increases of 122 and 128 per cubic millimeter, respectively, vs. 69 in MOTIVATE 2; P<0.001 for both comparisons in each study). Frequencies of adverse events were similar among the groups. CONCLUSIONS: Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV-1 who were receiving OBT. (ClinicalTrials.gov numbers, NCT00098306 and NCT00098722.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., et al. (1996) · Science · doi:10.1126/science.273.5283.1856 · Cited by 2,484
The role of a mutant CCR5 allele in HIV–1 transmission and disease progression
Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1240 · Cited by 1,358
Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., & Landau, N. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.621 · Cited by 1,353
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
(1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040022009 · Cited by 958
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Self-citationRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationEfficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Self-citation
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication
Karlas, A., Machuy, N., Shin, Y., Pleissner, K.-P., Artarini, A., Heuer, D., Becker, D., Khalil, H., Ogilvie, L. A., Hess, S., et al. (2010) · Nature · doi:10.1038/nature08760 · Cited by 695
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Comprehensive Review in Current Developments of Benzimidazole‐Based Medicinal Chemistry
Keri, R. S., Hiremathad, A., Budagumpi, S., & Nagaraja, B. M. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12462 · Cited by 394
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
Self-citationHIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors
Park, R. J., Wang, T., Koundakjian, D., Hultquist, J. F., Lamothe-Molina, P., Monel, B., Schumann, K., Yu, H., Krupzcak, K. M., Garcia-Beltran, W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3741 · Cited by 333
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Schall, T. J., & Proudfoot, A. E. I. (2011) · Nature Reviews Immunology · doi:10.1038/nri2972 · Cited by 318
Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
Simmons, J. D., Stein, C. M., Seshadri, C., Campo, M., Alter, G., Fortune, S., Schurr, E., Wallis, R. S., Churchyard, G., Mayanja-Kizza, H., et al. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0025-3 · Cited by 314
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Coiras, M., López-Huertas, M. R., Pérez-Olmeda, M., & Alcamí, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2223 · Cited by 288
Current status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
Applications of Next-Generation Sequencing Technologies to Diagnostic Virology
Barzon, L., Lavezzo, E., Militello, V., Toppo, S., & Palù, G. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12117861 · Cited by 271
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201248 · Cited by 254
Hultquist, J. F., Schumann, K., Woo, J. M., Manganaro, L., McGregor, M. J., Doudna, J., Simon, V., Krogan, N. J., & Marson, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.080 · Cited by 170
Chemokines in COPD: From Implication to Therapeutic Use
Henrot, P., Prevel, R., Berger, P., & Dupin, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112785 · Cited by 131
Tilton, J. C., Wilen, C. B., Didigu, C. A., Sinha, R., Harrison, J. E., Agrawal-Gamse, C., Henning, E. A., Bushman, F. D., Martin, J. N., Deeks, S. G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01109-10 · Cited by 110
Moranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37
Metadata
- Authors
- Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., & Mayer, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-02
- Volume
- 359
- Issue
- 14
- Pages
- 1429-1441
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985722970
- Cited by
- 752
- References
- 27
- FWCI
- 61.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.